Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Smith MA, et al. Among authors: kurmasheva rt. Pediatr Blood Cancer. 2015 Jan;62(1):91-8. doi: 10.1002/pbc.25201. Epub 2014 Sep 27. Pediatr Blood Cancer. 2015. PMID: 25263539 Free PMC article.
IRS-1: auditing the effectiveness of mTOR inhibitors.
Easton JB, Kurmasheva RT, Houghton PJ. Easton JB, et al. Among authors: kurmasheva rt. Cancer Cell. 2006 Mar;9(3):153-5. doi: 10.1016/j.ccr.2006.02.027. Cancer Cell. 2006. PMID: 16530700 Free article. Review.
Predicted mechanisms of resistance to mTOR inhibitors.
Kurmasheva RT, Huang S, Houghton PJ. Kurmasheva RT, et al. Br J Cancer. 2006 Oct 23;95(8):955-60. doi: 10.1038/sj.bjc.6603353. Epub 2006 Sep 5. Br J Cancer. 2006. PMID: 16953237 Free PMC article. Review.
Pediatric oncology.
Kurmasheva RT, Houghton PJ. Kurmasheva RT, et al. Curr Opin Chem Biol. 2007 Aug;11(4):424-32. doi: 10.1016/j.cbpa.2007.05.037. Epub 2007 Jul 24. Curr Opin Chem Biol. 2007. PMID: 17652007 Free PMC article. Review.
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.
Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ. Smith MA, et al. Among authors: kurmasheva rt. Pediatr Blood Cancer. 2012 Aug;59(2):329-32. doi: 10.1002/pbc.23319. Epub 2011 Sep 15. Pediatr Blood Cancer. 2012. PMID: 21922647 Free PMC article.
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA. Kolb EA, et al. Among authors: kurmasheva rt. Pediatr Blood Cancer. 2012 May;58(5):815-8. doi: 10.1002/pbc.23290. Epub 2011 Aug 16. Pediatr Blood Cancer. 2012. PMID: 22052798 Free PMC article. Clinical Trial.
89 results